All In Biotech

Drug Trial Radar · NCT02145338

Antibiotic Prophylaxis for Clean Intermittent Catheterisation

Antibiotic Treatment for Intermittent Bladder Catheterisation: A Randomised Controlled Trial of Once Daily Prophylaxis

Last checked: Nov 19, 2026Latest source record: Mar 30, 2018 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 404 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

404

Actual

Start

Sep 2013

Primary completion

Feb 22, 2017

Study completion Feb 22, 2017

Sponsor

Lead sponsor
Newcastle-upon-Tyne Hospitals NHS TrustAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
NHS Health Technology Assessment Programme; Newcastle University; Glasgow Caledonian University; University of Aberdeen; Cambridge University Hospitals NHS Foundation Trust; North Bristol NHS Trust; University of Southampton
First posted
May 22, 2014

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This research project is designed to find out whether people who suffer repeated urinary tract infections (UTI) related to the need to empty their bladders intermittently with a fine plastic tube (catheter); a process called clean intermittent self-catheterisation (CISC), benefit from taking continuous daily low-dose antibiotics (antibiotic prophylaxis). The investigators estimate that about 40,000 people in the United Kingdom need to use CISC regularly to empty their bladder either because of nerve damage such as multiple sclerosis or because of failure of the bladder muscle to contract, and of these about 25% (10,000 people) suffer frequent UTI. One way to reduce this problem may be to take a small daily dose of antibiotics and the study aims to find out whether such treatment is effective and worthwhile both for the people who suffer the problem and for the National Health Service (NHS). The two options to be compared in the trial are firstly, a once daily preventive dose (prophylaxis) of an antibiotic routinely used for this purpose (either nitrofurantoin or trimethoprim or cefalexin), and secondly no prophylaxis. The investigators think that an overall decrease of 20% or more in the frequency of UTI would be large enough for future patients using CISC who get troublesome recurrent UTIs to be offered antibiotic prophylaxis routinely. The investigators will also assess any harm caused by continuous use of antibiotics, particularly side effects for those people taking them and changes in the resistance of bacteria to these antibiotics. The investigators can then work out whether the balance between the benefits and harms make the use of prophylaxis worthwhile to people carrying out CISC and for the NHS as a whole.

Conditions

  • Urinary Tract Infections, Recurrent

Interventions

  • Nitrofurantoin or Trimethoprim or CefalexinDrug

    Antibiotic prophylaxis

  • No prophylaxisOther

    Discrete treatment courses of antibiotics as indicated by symptoms or signs of UTI.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Relative incidence of symptomatic antibiotic-treated UTITime frame: 12 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institute of Cellular Medicine, Newcastle University

    Newcastle upon Tyne, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.